Small Cap Feast

10th April 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings: 








Whats baking in the oven?

Potential Initial Public Offerings:


Reverse Takeovers:


Change of Market:

TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated proposition as a value alternative to full price specialist retailers. The Company is listed on the premium segment of the Main market of the London Stock Exchange. The Company has announced its intention to change to the AIM market on the 3 May 2024.


Banquet Buffet

Celsius Resources 0.725p £15.81m (CLA.L)
The copper and gold mining Company announces the extension of the exploration permit for the Sagay Copper Project, held under its Philippine subsidiary, Tambuli Mining Company, Inc located on the Island of Negros in the Philippines. The extension of EP-000003-VI was issued on 1 April 2024. The Company is in the process of completing the Environmental Impact Assessment for the Sagay Project as the basis for the issuance of an Environmental Compliance Certificate.

Epwin Group 84.5p £120.6m (EPWN.L)
The manufacturer of energy efficient and low maintenance building products announces its decision to extend its existing share buyback programme originally announced on 27 November 2023 (the Programme), following the anticipated completion today of the initial repurchase limit of 3m ordinary shares at a total cost of £2.3m. The Programme is today being extended to allow the Company to repurchase up to a further 3m ordinary shares from the date of this announcement.

e-therapeutics 10.25p £59.5m (ETX.L)
The Company integrating computational power and biological data to discover life-transforming RNAi medicines announces (1) a proposed fundraise of £28.9m at a price of 15p per Ordinary Share by funds managed by M&G Investment Management Limited and Richard Griffiths and his controlled undertakings, existing shareholders of the Company; and (2) the proposed cancellation of Admission of its Ordinary Shares to trading on AIM. The Company has a current cash position of approximately £18m and will subsequently explore the option of listing on NASDAQ in due course.

Fulcrum Metals 15.25p £7.6m (FMET.L)
The Company focused on mineral exploration and development in Canada announces that its wholly owned subsidiary Fulcrum Metals (Canada) Ltd (FMCL) has entered into an option agreement to acquire a 100% interest in the Sylvanite Gold Tailings project, located in Kirkland Lake, Ontario, Canada. Sylvanite, an ex-producing mine, is strategically located 3km from Fulcrum's Teck-Hughes Gold Tailings project, the Company's first tailings investment and significantly expands its footprint in the Kirkland Lake Gold Camp, one of the most productive gold camps in Canada.

Helium One Global 1.45p £53.9m (HE1.L)
The primary helium explorer in Tanzania provides an update on its Rukwa Project. Itumbula West-1 extended well test remains on track for early Q3 2024. An Environmental and Social Impact Assessment study has commenced as part of the Mining Licence conversion process. The Company has appointed a facilities management company to commence a design study for a helium production plant at Rukw. The Company is continuing to work with the Tanzanian Government and the Mining Commission to move the Rukwa Project towards commercialisation.

MC Mining 8.125p £33.6m (MCM.L)
The independent board committee (IBC) of MC Mining (MCM) refers to the A$0.16 off-market takeover offer by Goldway Capital Investment Limited (Goldway) for all of the shares in MCM not currently owned by associates of Goldway (Offer). The IBC notes that as at 8 April 2024 the Offer has now been declared unconditional by Goldway and that Goldway and the associated Consortium members have disclosed a relevant interest in 83.67% of the issued shares. The final consideration for the Offer has now been determined at GBP 0.08336 per MCM Share. The IBC believes that Shareholders should consider accepting the Offer.

IQE plc 23.975p £230.3m (IQE.L)
The global supplier of compound semiconductor wafer products and advanced material solutions announces an expansion of its partnership with Advanced Wireless Semiconductor Company (AWSC) with a multi-year supply agreement. IQE will supply AWSC with Gallium Arsenide (GaAs) wafers for the manufacture of smartphone power amplifier devices to be supplied to its key customer Lansus, the Chinese RF technology supplier. This will supply Tier One China-based OEMs in the Android ecosystem, in a market which is expected to return to growth following a period of inventory build-up.

Ondine Biomedical 7.75p £17.6m (OBI.L)
The Canadian life sciences Company announced that the private healthcare provider, HCA Healthcare UK, has approved the Steriwave light-activated antimicrobial developed by Ondine Biomedical Inc. (LON:OBI) for use in its healthcare facilities to prevent healthcare-associated infections (HAIs) and reduce the use of antibiotics. HCA Healthcare is the largest private healthcare provider in the world, and one of the leading private healthcare providers in the UK, where it operates over 30 healthcare facilities.

Sareum Holdings* 12.5p £12.0m (SAR.L)
The clinical-stage biotechnology Company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has issued 2.9m new ordinary shares to RiverFort Global Opportunities PCC Ltd (RiverFort), in accordance with the terms of the Facility as announced on 3 August 2023. The Company has drawn £2.3m to date pursuant from two prepayment deposits. After this issue of 2.9m shares to RiverFort, the Company now has an outstanding balance of circa £0.8m under the Facility. Any balances pursuant to the Facility are not due for repayment until August 2025 (Maturity Date) and the Company expects to settle all balances by the issuance of Subscription Shares prior to the Maturity Date. As noted in the RNS of 28 March 2024, Sareum does not intend to make any further withdrawals pursuant to the Facility with RiverFort.

Touchstone Exploration 47.5p £102.8m (SAAS.L)
The Calgary, Alberta based petroleum and natural gas Company provides an operational update. The Cascadura-3ST1 well has been cased and production testing is scheduled to commence in the third quarter of 2024 directly into the Cascadura natural gas facility. The CO-374 well has been cased for crude oil production and will be completed once the CO-375 development well has been drilled and the rig is moved from the location. Average net sales volumes was reported as 7,015 boe/d in the first quarter of 2024.

10 April 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram